Originally published In Press as doi:10.1074/jbc.M202965200 on April 10, 2002
J. Biol. Chem., Vol. 277, Issue 25, 22377-22385, June 21, 2002
Host Defense Responses to Infection by Mycobacterium
tuberculosis
INDUCTION OF IRF-1 AND A SERINE PROTEASE INHIBITOR*
Yaming
Qiao
,
Savita
Prabhakar
,
Eliana M.
Coccia§,
Michael
Weiden¶,
Antony
Canova
,
Elena
Giacomini§, and
Richard
Pine
From the
Public Health Research Institute, Newark,
New Jersey 07103, § Istituto Superiore di Sanità,
00161 Rome, Italy, and ¶ New York University School of Medicine
and Bellevue Hospital, New York, New York 10016
Received for publication, March 27, 2002, and in revised form, April 5, 2002
 |
ABSTRACT |
Alveolar macrophages and newly recruited
monocytes are targets of infection by Mycobacterium
tuberculosis. Therefore, we examined the expression of interferon
regulatory factor 1 (IRF-1), which plays an important role in host
defense against M. tuberculosis, in undifferentiated and
differentiated cells. Infection induced IRF-1 in both. IRF-1 from
undifferentiated, uninfected monocytic cell lines was modified during
extraction to produce specific species that were apparently smaller
than intact IRF-1. After infection by M. tuberculosis or
differentiation, intact IRF-1 was recovered. Subcellular fractions were
assayed for the ability to modify IRF-1 or inhibit its modification. A
serine protease on the cytoplasmic surface of an organelle or vesicle
in the "lysosomal/mitochondrial" fraction from undifferentiated
cells was responsible for the modification of IRF-1. Thus, the simplest
explanation of the modification is cleavage of IRF-1 by the serine
protease. Recovery of intact IRF-1 correlated with induction of a
serine protease inhibitor that was able to significantly reduce the
modification of IRF-1. The inhibitor was present in the cytoplasm of
M. tuberculosis-infected or -differentiated cells. It is
likely that induction of both IRF-1 and the serine protease inhibitor
in response to infection by M. tuberculosis represent host
defense mechanisms.
 |
INTRODUCTION |
Tuberculosis begins with inhalation of Mycobacterium
tuberculosis and infection of resident alveolar macrophages.
Inflammation induced by M. tuberculosis then recruits
monocytes (1), which also face infection in alveoli. The response of
monocytes to M. tuberculosis is likely to differ from that
of macrophages due to changes that occur during monocyte to macrophage
differentiation. To date, few studies have compared infection of
monocytes and macrophages. The human THP-1 cell line is a well
established model system for such studies (2-4). Growing THP-1 cells
are monocyte-like, but they stop proliferating and differentiate to a
macrophage-like state when treated with
12-O-tetradecanoylphorbol 13-acetate
(TPA).1 One useful way to
compare the two cell types is by examining the expression of the
transcription factor interferon regulatory factor 1 (IRF-1), since it
plays an important role in host defense against mycobacteria. For
example, mice having a null mutation in the IRF-1 gene are susceptible
to the normally non-pathogenic Mycobacterium bovis Bacille
de Calmette-Guérin (M. bovis BCG) (5) and are more
susceptible than wild-type mice to infection by M. tuberculosis (6).
IRF-1 is induced by many cytokines. It was purified, and its gene was
cloned in the course of studies on induction of type I interferons
(IFNs) (IFN
and IFN
) by virus infection (7) and on induction of
gene expression in response to IFN
(8). However, type II IFN
(IFN
) is far more potent than IFN
as an inducer of IRF-1, and
virus infection is a poor inducer (8). Thus, it is not surprising that
disruption of the IRF-1 gene prevents induction of some
IFN
-regulated genes, including inducible nitric-oxide synthase (5),
but has little effect on viral induction of type I IFN genes or
induction of gene expression by IFN
(9-11). The susceptibility of
IRF-1 null mutant mice to mycobacterial infection may be due to the
resultant disruption of the normal pathway of response to IFN
, since
null mutations in IFN
, its receptor, or inducible nitric-oxide
synthase also increase susceptibility to mycobacteria (5, 12, 13).
However, IRF-1 might also play a role independent of the IFN
system.
In the present study, we examined changes in IRF-1 DNA binding activity
and protein after mycobacterial infection. M. tuberculosis increased both and induced a serine protease inhibitor activity that
affected extraction of IRF-1. We suggest that induction of IRF-1 and
the protease inhibitor may be functionally related as host defense
responses to M. tuberculosis.
 |
EXPERIMENTAL PROCEDURES |
M. tuberculosis and Eukaryotic Cell Culture--
All
manipulations with viable M. tuberculosis were performed
under biosafety level 3 containment. A clinical isolate of M. tuberculosis, TN913, from the Public Health Research Institute Tuberculosis Center was grown in Middlebrook 7H9 broth as previously described (14).
THP-1 cells (3) obtained from the American Type Culture Collection were
maintained between 0.6 and 6.0 × 105/ml in RPMI 1640 supplemented with penicillin/streptomycin (BioWhittaker) and 10%
defined supplemented calf bovine serum (Hyclone). Before infection, as
previously described (15), cells were untreated or treated with 20 nM TPA (Sigma) for 24 h. As indicated, cells were
stimulated with recombinant human IFN
(a gift from Amgen) at 1 ng/ml
for the final 2 h before harvest for preparation of extracts.
Conditioned media (CM) were collected 3 days post-infection from
undifferentiated or TPA-treated THP-1 cells infected at the indicated
multiplicity of infection (m.o.i.) or from parallel, uninfected
cultures. The CM were sterilely filtered and used the same day or
stored at 4 °C for use the next day. THP-1 cells maintained in
complete media were collected by centrifugation, suspended as indicated
in CM, then grown for 3 days before harvest for preparation of extracts.
Experiments with primary cells were performed in accordance with all
applicable laws and regulations. Cells obtained from healthy volunteers
by bronchoalveolar lavage were suspended in RPMI 1640 plus 10% fetal
bovine serum (Hyclone), placed in cell culture flasks, and infected
with M. tuberculosis TN913 as previously described (15) for
~16 h. Uninfected cells were cultured in parallel. Nonadherent cells
then were removed with the media, and the adherent cells were washed
gently with phosphate-buffered saline (PBS). The remaining alveolar
macrophages were 90-95% pure based on microscopic examination of
morphology. Peripheral blood monocytes were purified with anti-CD14
monoclonal antibody from buffy coats obtained from healthy volunteers,
then cultured in RPMI 1640 plus 15% fetal bovine serum. Infection with
a single cell suspension of M. tuberculosis H37Rv at a
m.o.i. of ~1 was begun after 4 or 5 days of adherence-induced
differentiation and continued for ~16 h. Uninfected cells were
cultured in parallel.
Preparation of Lysates and Extracts--
All steps were
performed at 0-4 °C except as indicated. Media were removed from
adherent cells. The cells were washed once with PBS and then were
scraped into additional PBS. Undifferentiated, uninfected THP-1 cells
growing in suspension were collected by centrifugation, suspended in
PBS, collected again by centrifugation, and suspended again in PBS.
Cells that had been adherent or in suspension were then collected by
centrifugation. Lysates and extracts were prepared with non-ionic
detergent or without detergent. Lysates and extracts from cells
infected by M. tuberculosis were filter-sterilized before
removal from bio-safety level 3 containment.
For preparations with non-ionic detergent, cell pellets were suspended
in 4 volumes of buffer I (0.5% Nonidet P-40, 0.1 mM EDTA,
20 mM Hepes, pH 7.9, 10% glycerol, 1 mM
dithiothreitol, 0.4 mM phenylmethylsulfonyl fluoride
(PMSF), 3 µg/ml aprotinin, 1 µg/ml leupeptin, and 2 µg/ml
pepstatin) and incubated on ice for 10 min. As indicated, cells were
lysed, and extracts were prepared without protease inhibitors. Nuclei
were sedimented by centrifuging the lysates at 1,000 × g for 10 min. The supernatants were recovered and adjusted
to 0.3 M NaCl to produce the cytoplasmic extracts. The
nuclear pellets were suspended with buffer I, sedimented again by
centrifuging, and suspended with 4 volumes of buffer I plus 0.4 M NaCl. The suspended nuclei were incubated for 30 min with
occasional mixing. The suspensions were clarified by centrifuging at
15,000 × g for 10 min. The supernatants were recovered as the nuclear extracts. Extracts were frozen rapidly on crushed dry
ice and stored at
80 °C.
For preparations without detergent, cells were suspended in 9 volumes
of buffer II (10 mM Hepes, pH 7.9, 10 mM KCl, 3 mM MgCl2, 1 mM dithiothreitol) and
allowed to swell for ~20 min. A lysate was prepared by disruption in
a Dounce homogenizer with 25-40 strokes of a loose-fitting pestle to
achieve 80-90% lysis, as determined by microscopic examination.
Nuclei were then sedimented as described above. The supernatant was
recovered and adjusted by the addition of 1/3 volume of 40% glycerol,
0.4 M NaCl in buffer II to produce a cytoplasmic extract.
Nuclear pellets were resuspended in 3 volumes of buffer II containing
0.4 M NaCl and 10% glycerol. Suspended nuclei were
extracted as described above. Alternatively, the lysate was adjusted by
the addition of 1/3 volume of 40% glycerol, 0.4 M NaCl in
buffer II and used for subcellular fractionation.
Subcellular Fractionation--
Subcellular fractions prepared by
differential centrifugation are designated based on the well
established distribution of the predominant organelle(s) and vesicles
(16). Vesicles derived from plasma membrane trafficking compartments
including early or late endosomes, Golgi apparatus, and endoplasmic
reticulum are primarily in the "microsomal" fraction, whereas a
small portion of plasma membrane often sediments with nuclei (16-19).
All steps were performed at 0-4 °C. Adjusted lysate from Dounce
homogenization was centrifuged at 1,000 × g for 10 min
to sediment nuclei. The post-nuclear supernatant was removed
thoroughly, and a portion was set aside. The remainder was centrifuged
at 13,000 × g for 10 min to sediment lysosomes and
mitochondria. The post-lysosomal/mitochondrial supernatant was removed
thoroughly, and a portion was set aside. The remainder was centrifuged
at 130,000 × g for 1 h to sediment microsomes and
ribosomes. The post-microsomal/ribosomal supernatant, also called the
cytosol, was removed thoroughly. Each pellet was resuspended in the
same volume of the same buffer as the fraction that was its source.
Thus, equal volumes of each fraction are derived from equal numbers of
the initial cells.
Electrophoretic Mobility Shift Assay (EMSA)--
An EMSA was
carried out as previously described (20). The radiolabeled probe was an
oligonucleotide from
117 to
89 of the IFN
/
-stimulated gene
15, which includes the IFN-stimulated response element (21). Cell
lysates, extracts, subcellular fractions, immunodepleted extracts (see
below), partially purified IRF-1 (prepared by phosphocellulose
(Whatman P11) chromatography of nuclear extracts from IFN
-stimulated
HeLa cells), proteases, protease inhibitors, and control buffers were
included as indicated for individual assays. Unlabeled hepatocyte
nuclear factor 4 distal element (22) or IFN-stimulated response element
oligonucleotides were included at 100-fold molar excess to provide
nonspecific or specific competition, respectively, as indicated for
individual assays. All the components for each assay except reaction
buffer, nonspecific DNA, and oligonucleotides were assembled on ice.
Incubation was started by the addition of a mixture of these remaining
components and then carried out for 30 min at room temperature before
electrophoresis on 6% polyacrylamide gels at 4 °C with 20 mM Tris-borate, pH 8.3, 0.4 mM EDTA buffer.
Images were obtained, and results were quantified with a PhosphorImager
(Molecular Dynamics).
Immunodepletion--
All specific antibodies were directed
against human antigens. Rabbit anti-neutrophil/monocyte elastase and
anti-cathepsin G as well as purified human neutrophil/monocyte elastase
and cathepsin G were obtained from Calbiochem. Goat anti-secretory
leukocyte protease inhibitor (SLPI) and recombinant human SLPI were
obtained from R&D Systems. Anti-plasminogen activator inhibitor 2 (PAI-2) and recombinant human PAI-2 were obtained from American
Diagnostica. Normal rabbit or goat IgG obtained from Zymed
Laboratories Inc. was used as a nonspecific, control antibody for
the respective specific antibodies. Protein A- or protein
G-conjugated-Sepharose 4B beads were obtained from Zymed
Laboratories Inc. Immunodepletion was performed at 4 °C by
mixing 5 µl (5 µg) of control or specific antibody with 50 µl of
a cytoplasmic extract (~150 µg of protein) prepared in buffer I and
adjusted to 150 mM NaCl without or with added target
protein as an external standard for 2 h, adding 50 µl of a 50%
slurry of protein A or protein G beads (for reactions with rabbit or
goat antibodies, respectively) and mixing for 4 h more and then
recovering the beads by centrifugation at 12,000 × g
for 20 s. The immunodepleted supernatants were then removed. The
recovered beads were washed 3 times with buffer I plus 300 mM NaCl, and then bound material was eluted by boiling in
SDS-PAGE sample buffer for 3 min. Eluates were recovered after
centrifugation at 12,000 × g for 20 s. The
immunodepleted supernatants and the eluates were then frozen in crushed
dry-ice and stored at -80 °C.
To control for the efficiency of immunodepletion, elastase (1.5 µg),
cathepsin G (1 µg), SLPI (50 ng), or PAI-2 (750 ng) was added to an
extract, and immunodepletion was performed with the respective specific
antibody or the control antibody (data not shown). As judged by
immunoblot of the recovered supernatants and of the eluted
immunoprecipitates, the amount of each added protein that was
specifically removed was far in excess of the amounts of the endogenous
proteins, which were undetectable when extracts were directly assayed
by immunoblot. The control antibodies did not reduce
the amount of added target protein in the supernatants or recover
any in the immunoprecipitates.
Immunoblotting--
Cytoplasmic or nuclear extracts,
immunodepleted extracts, eluted immunoprecipitates, partially purified
IRF-1, and protein standards in cytoplasmic extract buffer all were
adjusted to 1× SDS-PAGE loading buffer before analysis by
immunoblotting. All samples were boiled for 3 min, electrophoresed on
10% SDS-polyacrylamide gels, and then transferred to nitrocellulose
membranes (Bio-Rad) by electroblotting. Membranes were blocked with
0.5% nonfat dry milk in PBS for detection of IRF-1 or with 5% nonfat
dry milk and 0.2% Tween 20 in PBS for detection of cathepsin G,
elastase, PAI-2, or SLPI. Rabbit polyclonal antiserum against human
IRF-1 (8) or the antibodies against the other antigens (described above) were added to the respective solution. Membranes were washed with PBS, then incubated with horseradish peroxidase-conjugated secondary antibodies. Goat anti-rabbit immunoglobulin G and rabbit anti-goat immunoglobulin G (Zymed Laboratories Inc.)
were used to detect rabbit and goat primary antibodies, respectively.
Membranes were washed with PBS, then incubated with LumiGLO
chemiluminescent substrate (Kirkegaard and Perry Laboratories). Signals
were detected with x-ray film.
 |
RESULTS |
Infection by M. tuberculosis Induces IRF-1--
We first
investigated whether infection of macrophages by M. tuberculosis would alter IRF-1 DNA binding activity as measured by
EMSA (Fig 1A). Alveolar
macrophages had clearly detectable constitutive IRF-1 DNA binding
activity (lane 1). The activity was near or below the lower
limit of detection in peripheral blood monocyte-derived macrophages and
THP-1 macrophages (lanes 5 and 9), as is typical
of many cells (8, 20, 23-27). In each case, infection induced IRF-1
DNA binding activity (lanes 3, 7, and 10). The slower mobility induced complex comigrates with
in vitro translated or partially purified full-length IRF-1
(lane 11) bound to the oligonucleotide probe (8). The
identity of the complexes was confirmed by use of specific competitor
oligonucleotide (for example, lanes 2, 4,
6, and 8) and by reaction with anti-IRF-1 antibody (data not shown). The faster mobility-induced complex, labeled
A, also contained a species of IRF-1. Altogether, total IRF-1 DNA
binding activity clearly increased upon infection. Quantification of
IRF-1 DNA binding activity relative to a nonspecific DNA-binding protein that served as an internal standard (Fig. 1B),
showed that infection with M. tuberculosis caused
full-length IRF-1 to increase ~4-fold in differentiated THP-1 cells
and monocyte-derived macrophages. The increase was ~2-fold in
alveolar macrophages compared with their unusually high constitutive
level of IRF-1. Thus, in primary macrophages and THP-1 macrophages,
infection by M. tuberculosis clearly resulted in induction
of IRF-1 DNA binding activity. The induced level of IRF-1 was similar
in the alveolar and monocyte-derived macrophages and somewhat lower in the THP-1 macrophages.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 1.
M. tuberculosis
(TB) infection induces IRF-1 in
macrophages. A, alveolar macrophages (Alveolar
Mø), peripheral blood monocyte-derived macrophages
(MDM), or THP-1 cells differentiated by treatment with TPA
(THP-1 Mø) were uninfected ( ) or infected (+) as
indicated. IRF-1 DNA binding activity was detected by EMSA of nuclear
extracts from cells lysed with non-ionic detergent. An EMSA of
partially purified full-length IRF-1 is shown as a standard for
comparison (std). EMSA binding reactions included
nonspecific (N) or specific (S) oligonucleotide
competitor as indicated. The typical protein-DNA complex containing
IRF-1 (Intact IRF-1), an additional complex containing a
species of IRF-1 (A), and a nonspecific complex
(ns) are indicated. B, specific IRF-1 DNA binding
activity in the typical complex indicated in panel A was
quantified relative to the indicated nonspecific complex, which serves
as an internal standard for the amount of protein included in each
assay and loaded in each lane.
|
|
M. tuberculosis infection of THP-1 monocytes also induced
IRF-1 DNA binding activity (Fig.
2A). Constitutive expression
of IRF-1 was quite low (lane 1). The complexes that were
detected (labeled A, B, and C)
migrated more rapidly than the typical complex containing full-length
IRF-1. Nuclear extracts from monocytes stimulated with IFN
produced
an increase in the rapidly migrating complexes, yet the typical complex
was not induced (lane 2). Compared with extracts from
uninfected, unstimulated cells, nuclear extracts from infected
monocytes yielded a complex that had the mobility of full-length IRF-1
bound to the IFN-stimulated response element (lane 3).
Furthermore, the abundance of complex A increased and that of complexes
B and C decreased. As in differentiated THP-1 cells and primary
macrophages, infection of undifferentiated THP-1 cells by M. tuberculosis led to an increase in total IRF-1 DNA binding
activity. When nuclear extracts of IFN
-stimulated infected monocytes
were assayed (lane 4), the typical complex formed
abundantly, whereas the complexes B and C were much less abundant than
after IFN
stimulation of uninfected cells. Recovery of full-length IRF-1 from THP-1 monocytes was a specific effect of infection by
M. tuberculosis. After infection by M. bovis BCG
at the same m.o.i. (lanes 5 and 6) or after
phagocytosis of latex beads (data not shown), predominantly faster
mobility IRF-1 complexes were detected. The complexes formed with
extracts from untreated or IFN
-treated infected monocytes had
essentially the same mobility as the complexes formed with extracts
from untreated or IFN
-treated THP-1 macrophages (compare lanes
3 and 4 with lanes 7 and 8). Thus, infection of THP-1 monocytes by M. tuberculosis and
differentiation increased formation of typical complexes and decreased
formation of rapidly migrating complexes detected by EMSA of the
respective nuclear extracts compared with extracts from uninfected,
undifferentiated cells.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 2.
Recovery of IRF-1 from THP-1 monocytes is
affected by M. tuberculosis infection or TPA-mediated
differentiation. THP-1 cells were uninfected ( TB),
infected by M. tuberculosis (+TB), infected by
M. bovis BCG (+BCG), or treated with TPA
(+TPA), as indicated. Cells were not further treated ( ) or
were treated with IFN for the last 2 h before harvest (+), as
indicated. Nuclear extracts were prepared from cells lysed with
non-ionic detergent. A, the DNA binding activity of IRF-1
species (intact IRF-1, A, B, and
C) was analyzed by EMSA. B, IRF-1 species
(intact IRF-1, A, B, and C)
were identified by immunoblot. Partially purified IRF-1 from HeLa cells
(std) was included as a standard for intact IRF-1.
Lane 1' is an overexposure of lane 1. ns, nonspecific complex.
|
|
Immunoblots were performed (Fig. 2B) to identify IRF-1
species present in the extracts that had been analyzed by EMSA.
Anti-IRF-1 antiserum detected a pattern of proteins that corresponded
precisely with the protein-DNA complexes detected by EMSA.
Constitutively expressed IRF-1 recovered from monocytes appeared as
three species, labeled A, B, and C
(lanes 1 and 1'). Each of those was induced by
IFN
(lane 2). Extracts of infected monocytes contained an additional, slower mobility IRF-1 species, and total recovery of IRF-1
increased (lane 3). IFN
treatment of infected monocytes strongly induced the additional IRF-1 species, and to a lesser extent,
higher mobility species were recovered. IRF-1 species A was
constitutively present in macrophage extracts (lane 5). Recovery of this species increased slightly, and the slowest mobility IRF-1 species was abundant in extracts from IFN
-treated macrophages (lane 6). Consistent with the EMSA results, the slower
mobility-induced species comigrated with in vitro translated
or partially purified full-length IRF-1 (lane 7) (8).
Comparison of the EMSA and immunoblot results indicated that the ratio
of IRF-1 DNA binding activity and protein were similar under all
conditions and for all species of IRF-1. There was also a close
correlation between the mobility of the protein-DNA complexes detected
by EMSA and the mobility of the IRF-1 protein species. Furthermore,
infection or differentiation led to decreased recovery of higher
mobility IRF-1 species and increased recovery of full-length IRF-1.
To unambiguously demonstrate which protein species was contained in
which protein-DNA complexes, we next performed two-dimensional analyses. To increase sensitivity, the extracts were prepared from
IFN
-treated cells. Fig. 3A
shows the results obtained with extracts from monocytes (left
panel) and macrophages (right panel). The initial
separation by EMSA (in a parallel lane not used for a
SDS-PAGE sample) is shown aligned in the same position as the lane used
for a SDS-PAGE sample. The immunoblot result from the SDS-PAGE
separations of the initial protein samples and the EMSA complexes
formed by those samples is shown beneath the EMSA separations.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
IRF-1/DNA complexes with differing mobility
contain IRF-1 species of differing size. A, monocytes
(untreated THP-1 cells, left panel) or macrophages (THP-1
cells treated for 3 days with TPA, right panel) were
stimulated for 2 h with IFN . Nuclear extracts were prepared
from cells lysed with non-ionic detergent. For each extract,
IRF-1·DNA complexes were resolved by EMSA in a pair of lanes, and the
lanes were cut apart. The complexes resolved in one lane of each pair
were detected with a PhosphorImager, and the other lane of the pair was
equilibrated with SDS-PAGE loading buffer then applied horizontally as
a sample for SDS-PAGE, with the top of the EMSA lane at the left. The
extract used for the EMSA applied to each gel was also loaded directly
for SDS-PAGE on the same gel (Input). Additionally, a sample
of macrophage extract (THP-1/+TPA +IFN ) was loaded next
to the monocyte extract on the SDS-PAGE used to resolve the proteins
bound in the EMSA of the monocyte extract (left panel) and
vice versa (THP-1/ TPA +IFN ; right
panel). IRF-1 species (Intact IRF-1, A,
B, and C) were separated by SDS-PAGE and detected
by immunoblot. The IRF-1·DNA complexes resolved by EMSA are shown
aligned above each immunoblot result in the same position as the lane
used for the SDS-PAGE sample. B, THP-1 cells that were
uninfected (left panel) or infected with M. tuberculosis for 3 days (right panel) were treated for
2 h with IFN . Extracts were prepared and analyzed as described
for panel A, except that the extract from infected cells was
not included on the SDS-PAGE used for extracts from uninfected cells,
and vice versa.
|
|
Each complex resolved by EMSA contained one species of IRF-1 that
precisely comigrated with a species resolved by SDS-PAGE alone. Thus,
each species of IRF-1 protein detected in extracts from monocytes was
found in only one of the complexes detected by EMSA, and the slower
mobility complex detected by EMSA of extracts from macrophages
contained full-length IRF-1. The two-dimensional analyses of extracts
from uninfected and infected monocytes (Fig. 3B) also showed
that one characteristic higher mobility IRF-1 species was present in
each protein-DNA complex resolved by EMSA of monocyte extract
(left panel) and that the slower mobility complex resolved
by EMSA of the extract from infected monocytes contained only
full-length IRF-1 (right panel). Thus, the complexes resolved by EMSA reflect the presence of the corresponding distinct species of IRF-1 and can be used as an assay for their abundance.
A Monocyte Membrane-bound Serine Protease Is Responsible for
Production of High Mobility IRF-1 Species--
We hypothesized that
the presence of higher mobility IRF-1 species was the result of
protease activity and found that full-length IRF-1 was recovered in
nuclear extracts when THP-1 monocytes were lysed with non-ionic
detergent and sufficient (2 mM) PMSF (Fig. 4A, lane 2). This
result suggested that higher mobility IRF-1 species were produced
during extraction, in which case they might also be produced in
vitro. A cytoplasmic extract from untreated THP-1 cells was
prepared after lysis with non-ionic detergent in the absence of
protease inhibitors. The extract was mixed with partially purified
IRF-1 in the absence or presence of protease inhibitors, and whether
high mobility IRF-1 species were produced was determined in an EMSA
(Fig. 4B). IRF-1 assayed with no extract produced the
typical protein-DNA complex expected for intact IRF-1 (lane
1). Addition of the extract (lane 2) produced the
specific species previously observed for endogenous IRF-1 recovered
from THP-1 monocytes. PMSF, which reversibly inhibits cysteine
proteases and irreversibly inhibits serine proteases, substantially
reduced production of higher mobility IRF-1 species (lanes 3 and 4). In contrast, E64, a specific cysteine protease
inhibitor, did not (lanes 5 and 6). To confirm
that the E64 was active, its ability to inhibit papain was tested.
Papain completely degraded IRF-1 (lane 7), but inclusion of
E64 at 50 µg/ml completely protected the IRF-1 against proteolysis
(lane 8). Thus, monocytes contain a serine protease that can
lead to production of higher mobility IRF-1 species in
vitro.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 4.
A serine protease in THP-1 monocytes is
responsible for production of higher mobility IRF-1 species.
A, nuclear extract was prepared from untreated ( ) or
IFN -treated (+) THP-1 monocytes that had been lysed with non-ionic
detergent in the presence of 2 mM PMSF. The DNA binding
activity of IRF-1 species (Intact IRF-1, A,
B, and C) was analyzed by EMSA. B,
partially purified IRF-1 was mixed with control buffer (no
add'n), with cytoplasmic extract prepared from THP-1 monocytes
lysed by Dounce homogenization, or with papain, a nonspecific cysteine
protease, as indicated. Protease inhibitors PMSF and E64 were included
as indicated. The DNA binding activity of IRF-1 species (Intact
IRF-1, A, B, and C) was analyzed
by EMSA. C, cytoplasmic extract from THP-1 monocytes lysed
with non-ionic detergent was immunodepleted with the indicated
antibodies. The indicated relative amount of each immunodepleted
extract (1× or 4×, equivalent to 0.5 and 2 µl of the starting
extract) was mixed with partially purified IRF-1. The DNA binding
activity of IRF-1 species (Intact IRF-1, A,
B, and C) was analyzed by EMSA.
|
|
We tested whether either of two major monocyte serine proteases, the
lysosomal enzymes neutrophil/monocyte elastase and cathepsin G, was
responsible for the appearance of high mobility IRF-1 species. Antibodies against them were used for immunodepletion of monocyte cytoplasmic extract prepared after lysis with non-ionic detergent in
the absence of protease inhibitors (Fig. 4C). Partially
purified IRF-1 (lane 1) yielded higher mobility species when
mixed with the extract after it had been immunodepleted with control
antibody (lanes 2 and 3), anti-cathepsin G
(lanes 4 and 5), or anti-elastase (lanes
6 and 7). The comparable result obtained with the
nonspecific and specific antibodies together with the confirmed ability
of the specific antibodies to immunodeplete their target proteins (see
"Experimental Procedures") indicate that these proteases did not
contribute to production of higher mobility IRF-1 species.
To further address the source of the protease, we performed EMSA in
which partially purified IRF-1 was mixed with cell lysate or classical
subcellular fractions (Ref. 16; see "Experimental Procedures"). For
these experiments, cells were lysed by Dounce homogenization without
detergent or protease inhibitors. Equal proportions of the lysate or
subcellular fractions were assayed on a per cell basis, and the samples
were in the same buffer. In one experiment, lysate was compared with
the nuclear pellet, and post-nuclear supernatant was prepared from that
lysate (Fig. 5A). The lysate
yielded high mobility IRF-1 species, and as expected (lane
1), the nuclear pellet did not (lane 2) and the
post-nuclear supernatant did (lane 3), as judged by
comparison to the complexes formed by the added partially purified
IRF-1 (lane 4). In a separate experiment (Fig.
5B), further differential centrifugation was performed to
fractionate the post-nuclear supernatant. The production of high
mobility species of IRF-1 that occurred upon incubation with the
post-nuclear supernatant (lane 1) was enhanced upon
incubation with the lysosomal/mitochondrial pellet (lane 2).
The post-lysosomal/mitochondrial supernatant (lane 3), the
microsomal/ribosomal pellet (lane 4), and the cytosol
(lane 5) each resulted in production of small amounts of the
high mobility species, as judged by comparison to the input of
partially purified IRF-1 for this assay (lane 6). This
distribution of activity in fractions obtained from cells lysed gently
without detergent indicates that the protease is located on the
cytoplasmic surface of an organelle/vesicle in the
lysosomal/mitochondrial pellet.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
The serine protease responsible for
production of higher mobility IRF-1 species is located on the
cytoplasmic face of an organelle or vesicle in the
lysosomal/mitochondrial subcellular fraction of THP-1 monocytes.
THP-1 cells were lysed by Dounce homogenization, and subcellular
fractions were prepared as described under "Experimental
Procedures." A and B, partially purified IRF-1
was incubated with lysate (L), with the resuspended pellet
(P), or the supernatant (S) obtained after the
indicated centrifugation or with control buffer ( ). The DNA binding
activity of IRF-1 species (Intact IRF-1, A,
B, and C) was analyzed by EMSA.
|
|
Regulation of Monocyte Protease Activity--
We prepared extracts
at various times after TPA treatment and performed EMSA to determine
the kinetics for recovery of intact IRF-1 during differentiation of
THP-1 cells (Fig. 6). The three characteristic complexes, A, B, and C, formed with an extract from
IFN
-treated monocytes (compare lanes 1 and 2).
Extracts prepared from IFN
-treated cells after 2 or 6 h of TPA
treatment yielded some of the complex that contains intact IRF-1
(lanes 3 and 4). An increased amount of
more rapidly migrating complex A and reduced amounts of
complexes B and C were also observed with these extracts. Intact IRF-1
was the major species recovered after cells were grown in the presence
of TPA for 16, 24, 48, or 72 h and stimulated with IFN
for the
final 2 h before extraction (lanes 5-10). Complex A,
the IFN
-induced complex that was predominant at earlier times, was
greatly reduced and only slightly inducible at 48 or 72 h after
TPA treatment, and complexes B and C were no longer detectable. The
concomitant loss of higher mobility IRF-1 species and appearance of
lower mobility species, culminating in recovery of predominantly intact
IRF-1, indicates that the protease activity responsible for production
of higher mobility species diminishes as differentiation proceeds.

View larger version (88K):
[in this window]
[in a new window]
|
Fig. 6.
Kinetics of recovery of intact IRF-1 during
TPA-induced differentiation of THP-1 cells. THP-1 cells were
treated with TPA for various times and either received no other
treatment or were stimulated with IFN for the last 2 h before
harvest, as indicated. Nuclear extracts were prepared from cells lysed
with non-ionic detergent. The DNA binding activity of IRF-1 species
(Intact IRF-1, A, B, and C)
was analyzed by EMSA. ns, nonspecific complex.
|
|
Autocrine or paracrine mechanisms could account for the effect of
M. tuberculosis infection on induction of IRF-1 and
regulation of the protease activity, since only 10-30% of monocytes
or 30-50% of macrophages in a culture are actually infected upon
incubation with M. tuberculosis. The effect of TPA might be
entirely direct or in part mediated by secreted factors. To examine
these possibilities, we grew THP-1 monocytes in CM obtained from THP-1
monocytes and macrophages that had been infected for 3 days or had been
cultured in parallel without infection. We then performed EMSA and
immunoblotting to examine the IRF-1 recovered by lysis and extraction
with non-ionic detergent (Fig. 7). The
constitutive and IFN
-induced IRF-1 species recovered from monocytes
grown in CM from uninfected monocytes (lanes 1 and
2 in panels A and B) were similar to
the species detected in extracts from monocytes grown in fresh media
(Fig. 2). The same was true when monocytes were grown in media
conditioned by growth of M. tuberculosis alone (data not
shown). However, a higher mobility species of IRF-1 were reduced, and
intact IRF-1 was detected in extracts from monocytes grown in CM from
monocytes infected at high m.o.i. (lane 5 in panel
A). This effect of growth in CM from infected monocytes was also
seen when the cells were treated with IFN
(lane 6 in
panels A and B). Growth of monocytes in
conditioned media from cells infected at low multiplicity after TPA
treatment led to a similar reduction in higher mobility species of
IRF-1 and an increase in intact IRF-1 as growth in CM from monocytes
infected at high m.o.i., which was again seen in cells treated with
IFN
(lanes 7 and 8 in panels A and
B). Conditioned media from cells grown for 4 days in the
presence of TPA had no effect on recovery of constitutive or
IFN
-induced IRF-1 from monocytes (lanes 9 and
10 in panels A and B). Thus, the
effect of TPA on recovery of IRF-1 from uninfected cells is not likely to be mediated indirectly by factors secreted in response to TPA treatment. Furthermore, because conditioned media from infected, TPA-treated cells had a greater effect than conditioned media from
monocytes infected at the same m.o.i. (compare lanes 7 and 8 with lanes 3 and 4), infection after
TPA treatment leads to greater production of the secreted factor(s)
that modulates the protease activity which mediates production of high
mobility IRF-1 species.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 7.
CM obtained after M. tuberculosis
infection of THP-1 cells affects the species of IRF-1 recovered
from THP-1 monocytes, but conditioned media obtained after TPA-mediated
differentiation does not. THP-1 cells were grown for 1 day in
fresh media, then resuspended in fresh media or various CM as indicated
and grown for 3 days. Cells received no other treatment ( ) or were
stimulated with IFN for the last 2 h before harvest (+), as
indicated. Nuclear extracts were prepared from cells lysed with
non-ionic detergent. A, the DNA binding activity of IRF-1
species (Intact IRF-1, A, B, and
C) was analyzed by EMSA. B, IRF-1 species
(Intact IRF-1, A, B, and C)
were identified by immunoblot.
|
|
Infection of Monocytes by M. tuberculosis or TPA-mediated
Differentiation Induces a Cytoplasmic Protease Inhibitor--
Recovery
of intact IRF-1 upon extraction of TPA-treated or infected monocytes
(Figs. 1 and 2) could be due to a decrease in the monocyte protease,
induction of a protease inhibitor, or both. To examine these
possibilities, we first tested the effect of adding cytoplasmic extract
from TPA-treated cells to cytoplasmic extract from untreated monocytes
on production of high mobility IRF-1 species (Fig.
8A). The input of partially
purified IRF-1 is shown in lane 1. Monocyte cytoplasmic
extract alone had no DNA binding activity (lane 2).
Incubation of this fraction with the partially purified IRF-1
eliminated the intact protein and produced higher mobility species, as
expected (lane 3). Increasing amounts of cytoplasmic extract
from TPA-treated cells added to monocyte cytoplasmic extract did not
produce any specific protein-DNA complexes (lanes 4,
6, and 8). When IRF-1 was also present, the intact protein was increasingly recovered, and the higher mobility species decreased correspondingly (lanes 5, 7,
and 9). Cytoplasmic extract from infected monocytes
similarly inhibited the monocyte protease (Fig. 8B). In this
experiment, most of the intact input IRF-1 (lane 1) was
converted to higher mobility species upon the addition of monocyte
cytoplasmic extract (lane 3). When the reactions included
increasing amounts of cytoplasmic extract from infected monocytes, the
protease in the cytoplasmic extract from uninfected monocytes was
increasingly inhibited, as evidenced by the increasing amounts of
intact IRF-1 and the decreasing amounts of higher mobility species that
were detected (lanes 5, 7, and 9). As
in the previous experiment, the monocyte extract alone had no DNA
binding activity (lane 2), and increasing amounts of extract
from infected monocytes did not produce any specific protein-DNA
complexes (lanes 4, 6, and 8). These
data demonstrate that a protease inhibitor was induced by TPA-mediated
differentiation or by infection with M. tuberculosis.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 8.
A serine protease inhibitor is induced by TPA
treatment or M. tuberculosis infection of THP-1 cells.
Partially purified IRF-1 (+) or buffer ( ) was incubated without or
with monocyte cytoplasmic extract, as indicated. Additional buffer
containing increasing amounts of cytoplasmic extract from TPA-treated
THP-1 cells (A) or THP-1 monocytes infected by M. tuberculosis (B) was included in the incubation, as
indicated. The DNA binding activity of IRF-1 species (Intact
IRF-1, A, B, and C) was analyzed
by EMSA.
|
|
To determine the subcellular localization of the protease inhibitor,
lysate from TPA-treated THP-1 cells was prepared without detergent or
protease inhibitors, then fractionated. EMSA was performed to examine
the effect of the lysate or subcellular fractions on the ability of
monocyte cytoplasmic extract to modify partially purified IRF-1 (Fig.
9A). Intact input IRF-1
(lane 1) was reduced by the monocyte cytoplasmic extract,
and higher mobility species were increased, as expected (lane
2). When supernatants from 1,000 × g (lane
3), 13,000 × g (lane 5), or
130,000 × g (lane 7) centrifugation of
lysates from TPA-treated cells were added to the assay, production of
higher mobility IRF-1 species was reduced, and slightly more intact
IRF-1 was recovered. In contrast, the addition to the assay of the
lysosomal/mitochondrial (13,000 × g) pellet from
TPA-treated cells resulted in a substantial loss of IRF-1 DNA binding
activity (lane 4), and the microsomal/ribosomal
(130,000 × g) pellet had only a slight inhibitory
effect on the monocyte protease (lane 6). Thus, the
particulate fractions contained little or none of the induced protease
inhibitor; it was recovered in the cytosol after extensive
centrifugation.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 9.
The induced serine protease inhibitor is
cytosolic. TPA-treated THP-1 cells were lysed by Dounce
homogenization, and subcellular fractions were prepared as described
under "Experimental Procedures." A, partially purified
IRF-1 was incubated without or with THP-1 monocyte cytoplasmic extract,
and as indicated, the supernatant (S) or the resuspended
pellet (P) was obtained after the indicated sequential
centrifugation of the lysate from the TPA-treated cells. Buffer ( )
was included in place of cytoplasmic extract and/or subcellular
fractions as indicated. The DNA binding activity of IRF-1 species
(Intact IRF-1, A, B, and C)
was analyzed by EMSA. B, cytoplasmic extract from THP-1
macrophages was immunodepleted with the indicated antibodies. The
indicated relative amount of each immunodepleted extract (1× or 4×,
equivalent to 1 and 4 µl of the starting extract) was mixed with
cytoplasmic extract from THP-1 monocytes and with partially purified
IRF-1. The DNA binding activity of IRF-1 species (Intact
IRF-1, A, B, and C) was analyzed
by EMSA. C, cytoplasmic extract was prepared from THP-1
monocytes that had been infected by M. tuberculosis
(TB) and was immunodepleted with the indicated antibodies.
An amount of each immunodepleted extract equivalent to 1 µl of the
starting extract was mixed with cytoplasmic extract from THP-1
monocytes and with partially purified IRF-1. The DNA binding activity
of IRF-1 species (Intact IRF-1, A, B,
and C) was analyzed by EMSA.
|
|
We attempted to determine whether SLPI or PAI-2 might be the inhibitor
induced by differentiation or M. tuberculosis infection of
THP-1 cells, because among cytoplasmic serine protease inhibitors, these two are known to be induced by monocyte differentiation or
bacterial infection (28-31). Their possible role after differentiation was examined first (Fig. 9B). Partially purified IRF-1
(lane 1) yielded higher mobility complexes A, B, and C when
mixed with monocyte extract (lane 2). Increasing amounts of
extract from TPA-treated cells first led to an increase in complex A
and then to the appearance of the intact IRF-1 complex and a decrease
in complex C whether the extract had been immunodepleted with control antibody (lanes 3 and 4), antibody against SLPI
(lanes 5 and 6), or antibody against PAI-2
(lanes 7 and 8). The possible role of SLPI and
PAI-2 in the effect of infection by M. tuberculosis was examined next (Fig. 9C). The complex formed by partially
purified IRF-1 (lane 1) and the complexes formed when
monocyte extract was added (lane 2) are shown for comparison
with the complexes formed after incubation of partially purified IRF-1
with extract immunodepleted by control antibody (lane 3),
anti-SLPI (lane 4), or anti-PAI-2 (lane 5). In
each case, upon the addition of the immunodepleted extract there was a
slight decrease in production of higher mobility IRF-1 species B and C,
and a small amount of intact IRF-1 was recovered. These data
demonstrate that the protease inhibitor was still present after
immunodepletion. The comparable result obtained with the nonspecific
and specific antibodies together with the confirmed ability of the
specific antibodies to immunodeplete their target proteins (see
"Experimental Procedures") indicate that neither SLPI nor PAI-2 was
the inhibitor induced by differentiation or infection.
 |
DISCUSSION |
A framework that includes seven major points summarizes the
results and conclusions of this study. First, infection of monocytes and macrophages by M. tuberculosis induces IRF-1, as judged
by its DNA binding activity (Figs. 1 and 2). Second, IRF-1 species having greater electrophoretic mobility than full-length IRF-1 are
obtained upon extraction of THP-1 monocytes that are uninfected or
infected by M. bovis BCG, and full-length IRF-1 is recovered only after infection by M. tuberculosis or TPA-induced
monocyte-to-macrophage differentiation (Fig. 2). Third, the IRF-1·DNA
complexes detected by EMSA each contain one characteristic species of
IRF-1 protein (Fig. 3). Fourth, a serine protease localized to the
cytoplasmic surface of an organelle or vesicle in the
lysosomal/mitochondrial fraction is apparently responsible for
production of the higher mobility IRF-1 species (Figs. 4 and 5). Fifth,
as judged by the recovered species of IRF-1, there are differences in
regulation of the change in protease activity due to TPA-induced
differentiation and due to infection. The response to TPA is clear
within 6 h and is nearly complete within 16 h (Fig. 6). It
occurs apparently independent of autocrine or paracrine pathways (Fig.
7). The effect of infection on the protease activity is minimal at
24 h post-infection2 and
involves factors secreted from cells during infection (Fig. 7). Sixth,
infection by M. tuberculosis or differentiation induces a
cytoplasmic serine protease inhibitor (Figs. 8 and 9). Thus, the
protease and inhibitor would be expected to interact physiologically, and that interaction is likely to account for recovery of intact IRF-1.
Seventh, induction of IRF-1 and a serine protease inhibitor by M. tuberculosis infection are likely to be host defense responses to
infection, because it is independently known that IRF-1 contributes to
host defense against mycobacteria and that serine protease inhibitors
can be induced by and protect against inflammatory stimuli.
Induction of IRF-1 by M. tuberculosis Infection--
Induction of
IRF-1 by M. tuberculosis infection of monocytes and
macrophages is likely to be a host-defense mechanism, because the
pleiotropic functions of IRF-1 in the immune system, such as antiviral
and antibacterial phenotypes, or involvement in production of NK cells
and development of Th1 cell-mediated responses all contribute to host
defense against infectious disease (reviewed in Ref. 32). Of particular
note, targeted disruption of the IRF-1 gene greatly reduces expression
of inducible nitric-oxide synthase in response to infection by M. bovis BCG and makes mice susceptible to infection by M. bovis BCG and M. tuberculosis (5, 6).
Cleavage of IRF-1 by a Monocyte Serine Protease--
Three
considerations strongly suggest, but do not prove, that cleavage of
IRF-1 by a serine protease directly yields higher mobility species of
IRF-1. First, truncated species of IRF-1 produce EMSA complexes of
higher mobility and have higher mobility on SDS-PAGE than intact IRF-1
(33). Second, the IRF-1 species recovered from THP-1 monocytes
correspond to those produced in vitro by incubation of
monocyte extracts or fractions with partially purified IRF-1. Third,
PMSF inhibits recovery of higher mobility IRF-1 species. Although the
apparent cleavage of IRF-1 occurred during nuclear extract preparation,
it clearly reflected physiological changes in a protease activity that
occurred upon infection of monocytic THP-1 cells by M. tuberculosis or their TPA-induced differentiation. This regulation
is likely to be a general characteristic of monocytic cells, since we
obtained the same higher mobility IRF-1 species in extracts of
undifferentiated U937 and NB4 monocytic cell lines and observed that
they yielded intact IRF-1 after TPA treatment.2
Major monocyte serine proteases such as cathepsin G and elastase are
localized within lysosomes or intracellular vesicles (reviewed in Ref.
34), but it is unlikely that production of high mobility IRF-1 species
was due to leakage of organelle or vesicle contents. Incubation of
cathepsin G or elastase with IRF-1 in vitro produced
patterns of cleavage products that differed from the characteristic
species of IRF-1 recovered from cells and produced by incubation of
IRF-1 with monocyte cytoplasmic extract in
vitro.3 Moreover, the
cytosol of cells lysed without detergent had little or none of the
activity that produced the characteristic IRF-1 species, and
immunodepletion of elastase and cathepsin G from monocyte
cytoplasmic extract did not change the pattern of species produced from
partially purified IRF-1.
A change from recovery of cleaved proteins to recovery of intact
proteins upon monocyte-to-macrophage differentiation has also been
described for the transcription factors SP1 and p65. Cleavage of p65
occurs during extract preparation (35); whether the cleavage of SP1
occurs physiologically has not been addressed (36). In contrast to the
recovery of intact IRF-1, it was not clear whether the increased
recovery of intact SP1 or p65 in extracts of differentiated cells
reflected induction of a proteinase inhibitor.
Induction of a Serine Protease Inhibitor--
Even without knowing
the identity of the protease inhibitor, since it is cytosolic, it is
reasonable to conclude that it could physiologically inhibit the serine
protease that we detected on the cytoplasmic surface of an organelle or
vesicle. It seems that neither of two likely candidates, SLPI and
PAI-2, mediate inhibition of the protease. Using antibodies against
SLPI and PAI-2 to immunodeplete cytoplasmic extract from infected THP-1
monocytes or from THP-1 macrophages did not affect the ability of the
extracts to inhibit cleavage of partially purified IRF-1 by cytoplasmic
extract from THP-1 monocytes. Moreover, the addition of recombinant
SLPI or recombinant PAI-2 to cytoplasmic extract from THP-1 monocytes had no effect, although they were able to strongly inhibit in vitro cleavage of partially purified IRF-1 by trypsin or urokinase plasminogen activator, respectively.3 Nonetheless, several
observations about SLPI and PAI-2 are relevant to the effects of
M. tuberculosis infection on protease inhibitor expression.
First, SLPI, apparently acting intracellularly (37), inhibits several
responses to LPS (31, 38). Second, PAI-2 induction by tumor necrosis
factor
or by Mycobacterium avium infection limits
apoptosis evoked by those inflammatory stimuli (29, 39, 40). Thus,
although M. tuberculosis infection causes apoptosis at least
in part through induction of tumor necrosis factor
(41), tumor
necrosis factor
induction of PAI-2 might also limit the extent of
apoptosis. It is believed that limiting apoptosis may serve to keep
bacteria intracellular and prevent dissemination within the host (29,
42). Third, M. tuberculosis infection and expression of
PAI-2, both, induce type I IFN production (15, 43), and type I IFN
contributes to host defense against M. tuberculosis through
mechanisms that are yet unknown (6). These observations suggest that,
like induction of IRF-1, induction of a serine protease inhibitor
is likely to be a defensive host response to M. tuberculosis infection.
 |
ACKNOWLEDGEMENTS |
We thank Karl Drlica for critically reading
the manuscript and Daniel Vapnek for providing recombinant human
IFN
.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant AI37877 (to R. P.) and a post-doctoral fellowship from the Heiser Program for Research in Leprosy and Tuberculosis (to S. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Public Health
Research Institute, 225 Warren Street, Newark, NJ 07103. E-mail: rpine@phri.org.
Published, JBC Papers in Press, April 10, 2002, DOI 10.1074/jbc.M202965200
2
Y. Qiao, A. Canova, and R. Pine, unpublished observations.
3
Y. Qiao and R. Pine, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
TPA, 12-O-tetradecanoylphorbol 13-acetate;
CM, conditioned media;
EMSA, electrophoretic mobility shift assay;
IFN, interferon;
IRF-1, interferon regulatory factor 1;
M. bovis BCG, M.
bovis Bacille de Calmette-Guérin;
m.o.i., multiplicity of
infection;
PAI-2, plasminogen activator inhibitor 2;
PBS, phosphate-buffered saline;
PMSF, phenylmethylsulfonyl fluoride;
SLPI, secretory leukocyte protease inhibitor.
 |
REFERENCES |
| 1.
|
Schmitt, E.,
Meuret, G.,
and Stix, L.
(1977)
Br. J. Haematol.
35,
11-17[Medline]
[Order article via Infotrieve]
|
| 2.
|
Tsuchiya, S.,
Kobayashi, Y.,
Goto, Y.,
Okumura, H.,
Nakae, S.,
Konno, T.,
and Tada, K.
(1982)
Cancer Res.
42,
1530-1536[Abstract/Free Full Text]
|
| 3.
|
Tsuchiya, S.,
Yamabe, M.,
Yamaguchi, Y.,
Kobayashi, Y.,
Konno, T.,
and Tada, K.
(1980)
Int. J. Cancer
26,
171-176[Medline]
[Order article via Infotrieve]
|
| 4.
|
Auwerx, J.
(1991)
Experientia
47,
22-31[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kamijo, R.,
Harada, H.,
Matsuyama, T.,
Bosland, M.,
Gerecitano, J.,
Shapiro, D., Le, J.,
Koh, S. I.,
Kimura, T.,
Green, S. J.,
Mak, T. W.,
Taniguchi, T.,
and Vilcek, J.
(1994)
Science
263,
1612-1615[Abstract/Free Full Text]
|
| 6.
|
Cooper, A. M.,
Pearl, J. E.,
Brooks, J. V.,
Ehlers, S.,
and Orme, I. M.
(2000)
Infect. Immun.
68,
6879-6882[Abstract/Free Full Text]
|
| 7.
|
Miyamoto, M.,
Fujita, T.,
Kimura, Y.,
Maruyama, M.,
Harada, H.,
Sudo, Y.,
Miyata, T.,
and Taniguchi, T.
(1988)
Cell
54,
903-913[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Pine, R.,
Decker, T.,
Kessler, D. S.,
Levy, D. E.,
and Darnell, J. E., Jr.
(1990)
Mol. Cell. Biol.
10,
2448-2457[Abstract/Free Full Text]
|
| 9.
|
Kimura, T.,
Nakayama, K.,
Penninger, J.,
Kitagawa, M.,
Harada, H.,
Matsuyama, T.,
Tanaka, N.,
Kamijo, R.,
Vilcek, J.,
Mak, T. W.,
and Taniguchi, T.
(1994)
Science
264,
1921-1924[Abstract/Free Full Text]
|
| 10.
|
Reis, L. F. L.,
Ruffner, H.,
Stark, G.,
Aguet, M.,
and Weissmann, C.
(1994)
EMBO J.
13,
4798-4806[Medline]
[Order article via Infotrieve]
|
| 11.
|
Matsuyama, T.,
Kimura, T.,
Kitagawa, M.,
Pfeffer, K.,
Kawakami, T.,
Watanabe, N.,
Kündig, T. M.,
Amakawa, R.,
Kishihara, K.,
Wakeham, A.,
Potter, J.,
Furlonger, C. L.,
Narendran, A.,
Suzuki, H.,
Ohashi, P. S.,
Paige, C. J.,
Taniguchi, T.,
and Mak, T. W.
(1993)
Cell
75,
83-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Cooper, A. M.,
Dalton, D. K.,
Stewart, T. A.,
Griffin, J. P.,
Russell, D. G.,
and Orme, I. M.
(1993)
J. Exp. Med.
178,
2243-2247[Abstract/Free Full Text]
|
| 13.
|
Flynn, J. L.,
Chan, J.,
Triebold, K. J.,
Dalton, D. K.,
Stewart, T. A.,
and Bloom, B. R.
(1993)
J. Exp. Med.
178,
2249-2254[Abstract/Free Full Text]
|
| 14.
|
Zhao, B. Y.,
Pine, R.,
Domagala, J.,
and Drlica, K.
(1999)
Antimicrob. Agents Chemother.
43,
661-666[Abstract/Free Full Text]
|
| 15.
|
Weiden, M.,
Tanaka, N.,
Qiao, Y.,
Zhao, B. Y.,
Honda, Y.,
Nakata, K.,
Canova, A.,
Levy, D. E.,
Rom, W. N.,
and Pine, R.
(2000)
J. Immunol.
165,
2028-2039[Abstract/Free Full Text]
|
| 16.
|
de Duve, C.
(1971)
J. Cell Biol.
50,
20-55
|
| 17.
|
Marino, M. W.,
Dunn, A.,
Grail, D.,
Inglese, M.,
Noguchi, Y.,
Richards, E.,
Jungbluth, A.,
Wada, H.,
Moore, M.,
Williamson, B.,
Basu, S.,
and Old, L. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8093-8098[Abstract/Free Full Text]
|
| 18.
|
Chang, K.-J.,
Bennett, V.,
and Cuatrecasas, P.
(1975)
J. Biol. Chem.
250,
488-500[Abstract/Free Full Text]
|
| 19.
|
Dunn, W. A.,
Hubbard, A. L.,
and Aronson, N. N., Jr.
(1980)
J. Biol. Chem.
255,
5971-5978[Abstract/Free Full Text]
|
| 20.
|
Pine, R.
(1997)
Nucleic Acids Res.
21,
4346-4354
|
| 21.
|
Reich, N.,
Evans, B.,
Levy, D.,
Fahey, D.,
Knight, E., Jr.,
and Darnell, J. E., Jr.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
6394-6398[Abstract/Free Full Text]
|
| 22.
|
Sladek, F. M.,
Zhong, W.,
Lai, E.,
and Darnell, J. E., Jr.
(1990)
Genes Dev.
4,
2353-2365[Abstract/Free Full Text]
|
| 23.
|
Pine, R.,
and Darnell, J. E., Jr.
(1989)
Mol. Cell. Biol.
9,
3533-3537[Abstract/Free Full Text]
|
| 24.
|
Parrington, J.,
Rogers, N. C.,
Gewert, D. R.,
Pine, R.,
Veals, S. A.,
Levy, D. E.,
Stark, G. R.,
and Kerr, I. A.
(1993)
Eur. J. Biochem.
214,
617-626[Medline]
[Order article via Infotrieve]
|
| 25.
|
Neish, A. S.,
Read, M. A.,
Thanos, D.,
Pine, R.,
Maniatis, T.,
and Collins, T.
(1995)
Mol. Cell. Biol.
15,
2558-2569[Abstract]
|
| 26.
|
Matikainen, S.,
Ronni, T.,
Hurme, M.,
Pine, R.,
and Julkunen, I.
(1996)
Blood
88,
114-123[Abstract/Free Full Text]
|
| 27.
|
Improta, T.,
and Pine, R.
(1997)
Cytokine
9,
383-393[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Chapman, H. A.,
Vavrin, J. Z.,
and Hibbs, J. B. J.
(1982)
Cell
28,
653-662[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Gan, H.,
Newman, G. W.,
and Remold, H. G.
(1995)
J. Immunol.
155,
1304-1315[Abstract]
|
| 30.
|
Genton, C.,
Kruithof, E. K.,
and Schleuning, W. D.
(1987)
J. Cell Biol.
104,
705-712[Abstract/Free Full Text]
|
| 31.
|
Jin, F.,
Nathan, C. F.,
Radzioch, D.,
and Ding, A.
(1998)
Infect. Immun.
66,
2447-2452[Abstract/Free Full Text]
|
| 32.
|
Pine, R.
(2002)
J. Interferon Cytokine Res.
22,
15-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Lin, R.,
Mustafa, A.,
Nguyen, H.,
Gewert, D.,
and Hiscott, J.
(1994)
J. Biol. Chem.
269,
17542-17549[Abstract/Free Full Text]
|
| 34.
|
Bird, P. I.
(1999)
Immunol. Cell Biol.
77,
47-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Franzoso, G.,
Biswas, P.,
Poli, G.,
Carlson, L. M.,
Brown, K. D.,
Tomita-Yamaguchi, M.,
Fauci, A. S.,
and Siebenlist, U. K.
(1994)
J. Exp. Med.
180,
1445-1456[Abstract/Free Full Text]
|
| 36.
|
Rao, J.,
Zhang, F.,
Donnelly, R. J.,
Spector, N. L.,
and Studzinski, G. P.
(1998)
J. Cell. Physiol.
175,
121-128[Cro |